Keywords: influenza treatment, Biota Holdings, CS-8958

Biota’s LANI Phase III clinical trials in Asia prove successful

Article | 10 August 2009

Print This

Australia’s Biota Holdings has announced successful results from the Asian Phase III clinical trials of CS-8958, its second generation ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in